Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • elafibranor

    - PMLiVE

    Novo Nordisk reports phase 3 data showing semaglutide reduces liver scarring

    Patients with MASH in the ESSENCE phase 3 trial show semaglutide’s potential to improve liver health

    - PMLiVE

    Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn

    The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials

    - PMLiVE

    Ipsen’s tumour treatment receives MHRA marketing authorisation

    This is the first approval in the UK for previously treated advanced neuroendocrine tumours

    - PMLiVE

    Roche to acquire 89bio in a deal worth up to US$3.5bn

    With the agreement, Roche will gain a treatment for moderate to severe MASH

    - PMLiVE

    Ipsen receives EC approval for Cabometyx in advanced neuroendocrine tumours

    Treatment options following disease progression have previously been limited for many patients

    - PMLiVE

    Ipsen receives CHMP recommendation for Cabometyx in neuroendocrine tumours

    The number of patients newly diagnosed with NETs is believed to be on the rise

    - PMLiVE

    GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn

    Steatotic liver disease affects approximately 5% of the global population

    - PMLiVE

    Madrigal’s liver disease drug Rezdiffra shows promise in compensated MASH cirrhosis

    The drug has already been approved in the US to treat patients with non-cirrhotic MASH

    - PMLiVE

    Ipsen’s elafibranor shows promise in rare liver disease primary sclerosing cholangitis

    The drug already holds approvals to treat primary biliary cholangitis, another rare liver disease

    - PMLiVE

    Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis

    The life-long condition affects approximately 1,900 people in Scotland

    - PMLiVE

    Gilead’s seladelpar granted conditional EC approval to treat rare liver disease PBC

    Primary biliary cholangitis affects approximately 163,000 people in Europe

    - PMLiVE

    Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults

    The company gained access to the drug through its $4.3bn acquisition of CymaBay

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links